2025-02-23T03:33:40-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: Query fl=%2A&wt=json&json.nl=arrarr&q=id%3A%22irk-123456789-194565%22&qt=morelikethis&rows=5
2025-02-23T03:33:40-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: => GET http://localhost:8983/solr/biblio/select?fl=%2A&wt=json&json.nl=arrarr&q=id%3A%22irk-123456789-194565%22&qt=morelikethis&rows=5
2025-02-23T03:33:40-05:00 DEBUG: VuFindSearch\Backend\Solr\Connector: <= 200 OK
2025-02-23T03:33:40-05:00 DEBUG: Deserialized SOLR response

Use IR-spectroscopy in treatment oncological patients with bone metastasises by ¹⁵³Sm-oxabifor

Using infrared spectroscopy, we studied the character of intermolecular interactions in the samples blood plasma of oncological patients with bone metastases in the treatment of their modern β-emitter ¹⁵³Sm-oxabifor. The therapeutic dose of the ¹⁵³Sm-oxabifor was 1.0 mCi/kg of the patient’s body wei...

Full description

Saved in:
Bibliographic Details
Main Authors: Dikiy, N.P., Krasnoselsky, N.V., Bereznyak, E.P., Grushka, A.V., Medvedeva, E.P.
Format: Article
Language:English
Published: Національний науковий центр «Харківський фізико-технічний інститут» НАН України 2020
Series:Вопросы атомной науки и техники
Subjects:
Online Access:http://dspace.nbuv.gov.ua/handle/123456789/194565
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Using infrared spectroscopy, we studied the character of intermolecular interactions in the samples blood plasma of oncological patients with bone metastases in the treatment of their modern β-emitter ¹⁵³Sm-oxabifor. The therapeutic dose of the ¹⁵³Sm-oxabifor was 1.0 mCi/kg of the patient’s body weight. Analysis of the IR spectra showed that already after the first course of palliative radionuclide therapy there is a tendency to balance the products of free radical nature and antioxidants, which indicates the effectiveness of the treatment. Molecular changes in the blood plasma of cancer patients with bone metastases registered using infrared spectroscopy are specific during palliative therapy.